Roadshow
PCR-CE Fragile X Syndrome Genetic Testing Kit
Uses polymerase chain reaction (PCR) to amplify the FMR1 gene including the CGG repeats. PCR product is analyzed by high-resolution capillary electrophoresis. Provides a reference sample which contains different CGG repeats. The reference sample can create a equation of linear regression standard curve to calculated the CGG repeats.
Join us at BIO 2024, June 3-6 in San Diego, where Origin Biotechnology Co., Ltd. be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1917. See you there! #BIO2024#TAIWAN PAVILION
Fragile X syndrome
Fragile X syndrome (FXS) is the most commonly diagnosed inherited cause of intellectual disability. The prevalence is second only to Down syndrome as a cause of intellectual disability.It is difficult to detect Fragile X syndrome by chromosome karyotyping or aCGH. Most newborns do not show any physical signs of FXS, so the early diagnosis of FXS or carrier status is important. FXS can be diagnosed using FMR1 DNA test by polymerase chain reaction (PCR).
Fragile X syndrome (FXS) is a genetic condition caused by an abnormal expansion of CGG triplet repeat within the Fragile X mental retardation 1 (FMR1) gene, a gene located on the X chromosome. In unaffected individuals, the FMR1 gene contains 5–44 repeats of the sequence CGG. Between 45-54 repeats is considered intermediate and usually do not exhibit any symptom of FXS or FMR1-related disorders. Individuals with a premutation allele generally considered to be between 55 and 200 repeats. Individuals with fragile X syndrome have a full mutation of the FMR1 allele, with over 200 CGG repeats. The general prevalence with a full mutation is estimated at 1/3,600 males and 1/5000 females. Approximately 1/250 females and 1/800 males carry premutation alleles.
Features and advantages
- #Fragile X Syndrome
- #Primary Ovarian Insufficiency
- #Autism Spectrum Disorder
- #Tremor/Ataxia
- #Spinal Muscular Atrophy
- #Duchenne Muscular Dystrophy
- #Kawasaki Disease
- #Thalassemia
- #Carrier Screening
- #Prenatal Screening
- Established 2018
- Company Origin Biotechnology Co., Ltd.
- Telephone +886-2-3393-1118
- Email yuwei@oribio.com.tw
- Address 5F.-1, No. 12, Linsen S. Rd., Zhongzheng Dist., Taipei City, 10050, Taiwan
Origin Biotechnology Co., Ltd. is an innovative biotechnology company with independent research and development. Our focus lies in the development of rapid and accurate molecular detection technologies and products, with a specific emphasis on the prevention, screening, and diagnosis of maternal and child health as well as genetic diseases.
Possessing multiple channels of access to Chinese hospitals, assisting in market development, acting as agents in the Chinese market, and assisting in obtaining NMPA (National Medical Products Administration) licenses in China.
